On February 24, 2023, a subsidiary of Hempire Technology Group was granted a patent in Japan ( Patent No. 特許第7220818号), which will accelerate the group's research and development and implementation of products for the treatment of neurodegenerative diseases in the country. This patent has previously been approved in mainland China, the United States, and Hong Kong, and its protection will eventually cover other major countries and regions worldwide.

Japan has a relatively large number of patients with neurodegenerative diseases globally. According to data, the number of patients with cognitive impairment (including Alzheimer's disease) and Parkinson's disease has exceeded 6.2 million people and will reach nearly 8 million people by 2030. The total social burden brought by related diseases to Japan will be as high as 660 billion US dollars.

Currently, countries such as Japan and the United States have identified the development of THC-free cannabinoid drugs as a key focus of medical cannabis industry development. The Ministry of Health, Labour and Welfare of Japan has already led the related research, and the Japanese government is considering submitting a bill to revise the Cannabis Control Law during this session of the Diet, allowing the use of medical cannabis products for the treatment of diseases. The patent obtained by the group in Japan and its future applications are fully consistent with the industrial direction formulated by the Japanese government.